Association Between Cardiovascular Disease and Breast Cancer Stage at Diagnosis Academic Background Cardiovascular disease (CVD) and cancer are the two leading causes of mortality in the United States. Although they share many common risk factors, recent studies suggest that CVD may directly promote the occurrence and progression of cancer. Specifi...

Academic Background and Problem Statement Fibroblast growth factor receptor inhibitors (FGFRi) are a class of targeted drugs used to treat intrahepatic cholangiocarcinoma (iCCA). Although FGFRi has shown significant efficacy in treating iCCA, the potential complications associated with their long-term use have not been fully studied. In particular,...

The Impact of Soluble B-Cell Maturation Antigen (sBCMA) on Multiple Myeloma Therapy: Interpreting the Latest Research Findings In recent years, cell-based immunotherapies have demonstrated enormous promise in the treatment of multiple myeloma (MM). Among these, BCMA-targeting T-cell engagers (TCEs) and chimeric antigen receptor (CAR) T-cell therapi...

Review of the Impact of FISH-Detected Cytogenetic Abnormalities on Prognosis in AL Amyloidosis in the Era of Daratumumab Therapy Background Immunoglobulin light chain (AL) amyloidosis is a rare disease characterized by organ dysfunction caused by the deposition of light chain proteins secreted by abnormal plasma cells. However, the heterogeneous cl...

Progress in Molecular Classification of Follicular Lymphoma: A Dual Typing Predictive Model Based on RNA Sequencing and Immunohistochemistry Follicular Lymphoma (FL) is a B-cell malignancy characterized by a slow clinical progression, with a median overall survival extending up to 20 years. However, the heterogeneous nature of FL leads to significa...

Research on Juvenile Xanthogranuloma Reveals Novel Genetic Mutations Juvenile xanthogranuloma (JXG), a rare histiocytic neoplasm, typically manifests in the skin but occasionally presents extracutaneously in locations such as soft tissue or the central nervous system (CNS). The genetic drivers underlying these extracutaneous variants remain poorly ...